Brivaracetam for Epilepsy
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of the study is to investigate the long-term safety, tolerability and efficacy of brivaracetam in pediatric study participants with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).
Who Is on the Research Team?
UCB Cares
Principal Investigator
001 844 599 2273 (UCB)
Are You a Good Fit for This Trial?
This trial is for children and young adults aged 2 to 26 with Childhood Absence Epilepsy or Juvenile Absence Epilepsy. Participants must not be pregnant, breastfeeding, and if sexually active, agree to use contraception. They should have no severe medical issues or history of non-epileptic seizures and not be at risk of suicide.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive brivaracetam doses as oral solution or film-coated tablet twice per day
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension
Participants continue to receive brivaracetam to evaluate long-term safety, tolerability, and efficacy
What Are the Treatments Tested in This Trial?
Interventions
- Brivaracetam
Brivaracetam is already approved in European Union, United States, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
UCB Biopharma SRL
Lead Sponsor
Jean-Christophe Tellier
UCB Biopharma SRL
Chief Executive Officer since 2015
MD from University of Reims Champagne-Ardenne, Rheumatology specialization from University of Paris V, Executive business programs at Harvard and INSEAD
Dr. Iris Loew-Friedrich
UCB Biopharma SRL
Chief Medical Officer since 2014
MD from University of Leuven, PhD in Medical Sciences from University of Leuven